The 2nd International Electronic Conference on Vaccines
The 2nd International Electronic Conference on Vaccines
Part of the International Electronic Conference on Vaccines series
Event's Timezone: Central European Time
16th September 2024
30th September 2024
24th November 2024
Immunology Mechanisms, Animal Models for Immunologic Diseases, Viral Immunology, Immunopathogenesis, Vaccine Development and Efficacy Evaluation, Immune Responses to Vaccines, Vaccine Technology, Vaccine Vectors Adjuvants and Immunomodulators
The submission of abstracts has been closed. Don't miss the opportunity and click this link to REGISTER.
IECV 2024 will be FREE for Participation!
Welcome from the Chair
There are currently major challenges to developing new vaccines and improving existing platforms for both infectious diseases and cancer. Novel methods of vaccine delivery for both human and different animal species are required. Advances in vaccine design to give broad protection to mitigate against the mutation of antigens and to provide both good humoral and cellular immunity are a priority. For flaviviruses, particularly dengue, there are major hurdles to producing vaccines, which not only cover all the serotypes but also prevent the induction of antibody-dependent enhancement. Inactivated and subunit vaccines need to be combined with effective long-acting adjuvants to optimise their potential. In all cases, novel assays, in particular omics-based approaches, are necessary to evaluate in-depth and early responses to vaccination.
The IECV 2024 invites researchers from academia, as well as vaccine practitioners, to contribute original findings, novel ideas, scientific concepts, and new technologies and experiences to deal with immunology mechanisms, animal models for immunologic diseases, viral immunology, immunopathogenesis, vaccine development and efficacy evaluation, immune responses to vaccines, vaccine technology, vaccine vectors, adjuvants, and immunomodulators, with reference to the following topics:
Cancer vaccines, immunotherapy, and immunoprevention;
Challenges of developing a dengue vaccine;
Vaccine adjuvants;
mRNA vaccines;
Advancement in vaccine design for broad protection;
Novel assays for evaluating responses to vaccination.
The conference will be held entirely online, allowing people from all around the world to participate without any concerns about travel or related expenses. An electronic conference offers a platform for quick and direct exchanges of the latest research findings and innovative ideas.
The vaccine scientific community's support and enthusiasm are greatly appreciated, as you play a crucial role in ensuring the success of this 2nd edition of IECV. Your contribution will pave the way for many more successful editions in the future.
Kind regards,
Professor Sara Louise Cosby
School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK
Virology, Veterinary Sciences Division, Agri-Food and Biosciences Institute, UK
Program Overview
| 27th November - Morning | 28th November - Morning | 29th November - Morning |
|
Session 5. Advancement in Vaccine Design for Broad Protection |
Session 3. Vaccine Adjuvants | |
| 27th November - Afternoon | 28th November - Afternoon | 29th November - Afternoon |
|
Session 1. Cancer Vaccines, Immunotherapy, and Immunoprevention |
Session 6. Novel Assays for Evaluating Responses to Vaccination |
Session 4. mRNA Vaccines Session 2. Challenges of Developing a Dengue Vaccine |
IECV 2024 Program (DAY 1)
IECV 2024 Day 1
Session 5. Advancement in Vaccine Design for Broad Protection
Date: 27th November 2024 (Wednesday)
Time: 9:00 (CET, Basel) | 03:00 (EDT, New York) | 16:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 09:00-09:15 | Professor Sara Louise Cosby Event Chair |
Welcome from the Event Chair |
| 09:15-09:45 | Prof. Dr. Martin Bachmann Keynote Speaker |
Companion animals as link for the development of therapeutic vaccines in humans |
| 9:45-10:00 | Dominik Rothen | Preclinical evaluation of novel sterically optimized VLP-based vaccines against all four DENV serotypes |
| 10:00-10:15 | Gianmarco Ferrara | An Evaluation of the humoral response following two doses of a Coxiella burnetii vaccine in water buffalo |
| 10:15-10:30 | Xinyue Chang | Virus-like particle-derived vaccine induces broad neutralising antibodies against porcine epidemic diarrhea virus (PEDV) |
| 10:30-10:45 | Victoria Jane Smyth | Evaluation of Chicken Astrovirus Breeder Vaccine Candidate |
| 10:45-11:00 | Zilu Ma | Lysosome-Associated Membrane Protein Targeting Strategy Improved Immunogenicity of Glycoprotein-Based DNA Vaccine for Hantaan virus |
| 11:00-11:15 | Dudnikova Ekaterina Nikolaevna |
The dynamics of the incidence of vaccine-controlled infections in the southern federal district of the russian federation from 2010 to 2023 |
| 11:15-15:00 | BREAK |
Session 1. Cancer Vaccines, Immunotherapy and Immunoprevention
Session 5. Advancement in Vaccine Design for Broad Protection
Date: 27th November 2024 (Wednesday)
Time: 15:00 (CET, Basel) | 09:00 (EDT, New York) | 22:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 15:00-15:15 | Prof. Dr. Mona O. Mohsen Session Chair |
Welcome from the Session Chair |
| 15:15-15:45 | Professor Roger Geiger Invited Speaker |
Metabolic modulation of tumors with engineered bacteria for cancer immunotherapy |
| 15:45-16:15 | Prof. Dr. Eva Sevick Keynote Speaker |
Improving checkpoint blockade immunotherapy with vaccination and lymphatic delivery |
| 16:15-16:30 | Romano Josi | Intranasal administration of a tetravalent nanovaccine inhibits growth of HPV-associated head and neck orthotopic tumors in a murine model |
| 16:30-16:45 | Arnau Solé Casaramona | Cutting-Edge: Unleashing the Potential of γδ T Cells with Novel Nanoparticles for Cancer Immunotherapy Applications |
| 16:45-17:05 | Professor Seth Pincus Invited Speaker |
Using Cytotoxic Immunoconjugates to Eradicate Persistent Viral Reservoirs |
| 17:05-17:20 | Silvia A. Sousa | Exploiting surface-exposed proteins to develop new therapeutic strategies against Bcc and Pseudomonas aeruginosa infections |
| 17:20-17:35 | Veronica Araceli Marquez-Escobar | Synthesis and characterization of zein nanoparticles for antigen delivery |
IECV 2024 Program (DAY 2)
IECV 2024 Day 2
Session 3. Vaccine Adjuvants
Date: 28th November 2024 (Thursday)
Time: 9:00 (CET, Basel) | 03:00 (EDT, New York) | 16:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 09:00-09:10 | Prof. Dr. Silvio Tafuri & Dr. Srinivasa Reddy Bonam Session Chairs |
Welcome from the Session Chairs |
| 09:10-09:40 | Dr. Antonio Di Lorenzo Keynote Speaker |
TBA |
| 09:40-09:55 | Fusako Mitsunaga | Efficacy, Safety, and Molecular Mechanism of Sublingual Poly(I:C)-Adjuvanted Vaccine Formulated with SARS-CoV-2 RBD or Influenza HA Antigen in Non-Human Primates, Macaque Monkeys |
| 09:55-10:10 | Kishore Alugupalli | Turbo: an adjuvant platform for bacterial glycoconjugate vaccines |
| 10:10-10:25 | Xinliang Kang | Overcoming Aging-Associated Poor Influenza Vaccine Responses with CpG 1018 Adjuvant |
| 10:25-14:00 | BREAK |
Session 6. Novel Assays for Evaluating Responses to Vaccination
Date: 28th November 2024 (Thursday)
Time: 14:00 (CET, Basel) | 08:00 (EDT, New York) | 21:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 14:00-14:10 | Prof. Dr. Seth Pincus & Dr. Tan Yee Joo Session Chairs |
Welcome from the Session Chairs |
| 14:10-14:30 | Dr. Tan Yee Joo Keynote Speaker |
Establishing surrogate assays to measure antibodies inhibiting multiple subtypes of influenza A virus |
| 14:30-15:00 | Dr. Paul Engeroff Invited Speaker |
Allergy Immunotherapy: Considering Immune Complexes |
| 15:00-15:15 | Milagros Virhuez Mendoza | Distinguishing the antibodies induced by the live attenuated vaccine (LC16m8) and orthopoxvirus infections |
| 15:15-15:30 | Valeria Perniola |
Covid-19, influenza, and pneumococcus vaccinal status among hospitalized patients during the Covid-19 pandemic era |
| 15:30-15:45 | Zilu Ma | Immunoreactivity Analysis of MHC-I Epitopes Derived from the Nucleocapsid Protein of SARS-CoV-2 via Vaccination |
| 15:45-16:00 | Alvaro Munaylla | In silico design of a vaccine candidate against Oropouche virus based on a multi-epitope protein |
IECV 2024 Program (DAY 3)
IECV 2024 Day 3
Session 4. mRNA Vaccines
Session 2. Challenges of Developing a Dengue Vaccine
Date: 29th November 2024 (Friday)
Time: 14:00 (CET, Basel) | 08:00 (EDT, New York) | 21:00 (CST Asia, Beijing)
| Time in CET | Speaker | Title |
| 14:00-14:10 | Dr. Jorge H. Leitão & Dr. Srinivasa Reddy Bonam Session Chairs |
Welcome from the Session Chairs |
| 14:10-14:40 | Professor Gerald Barry Invited Speaker |
Analysis of bovine coronavirus sequences circulating in Ireland and development of a prototype, species specific, mRNA vaccine, targeting this virus |
| 14:40-14:55 | Rabaï Bouderhem | Regulating the use of AI in mRNA vaccine development through policy coherence |
| 14:55-15:10 | Noe Juvenal Mendoza-Ramírez | DNA immunization with a plasmid that codifies O-SN SARS-CoV-2 fusion protein induced effective humoral and cellular immune response in a preclinical model |
| 15:10-15:55 | Dr. Henry Puerta-Guardo & Dr. Bapi Pahar Session Chairs |
Welcome from the Session Chairs |
| 15:15-15:35 | Dr. Henry Puerta-Guardo Session Chair |
Challenges of Developing a Dengue Vaccine: a state of the art |
| 15:35-16:05 | Dr. Byron Martina Keynote Speaker |
TBA |
| 16:05-16:20 | Hector Hernando Gutierrez Barbosa | A comparison of Humanized mice models using NOD-derived strains for Dengue virus infection |
| 16:20-16:35 | Arturo Linan-Torres |
Development of a dual vaccine candidate against dengue and zika viruses by presenting a mimotope on the capsid of adeno-associated virus serotype 8 |
Event Chair
1. School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK,
2. Virology, Veterinary Sciences Division, Agri-Food and Biosciences Institute, UK
Professor Sara Louise Cosby is a graduate (B.Sc. and Ph.D. in Microbiology, Queen’s University Belfast (QUB), a Fellow of the Royal College of Pathologists (speciality Virology) and Fellow of the Royal Society of Biology (RSB). Louise is Head of Virology at the Agri-Food and Biosciences Institute in Belfast and an honorary/emeritus Professor in the Wellcome Wolfson Institute for Experimental Medicine, in the School of Medicine Dentistry and Biomedical Sciences (MDBMS), QUB. She previously held the Chair of Microbiology in the School of MDBMS. As Head of Virology at AFBI, she oversees international research programmes and is responsible for virus molecular and immune diagnostics for epizootic animal diseases. Louise’s research has focused on elucidation of pathogenic mechanisms of measles virus, the closely related veterinary morbilliviruses and more recently bovine respiratory syncytial, herpes and corona viruses. Louise is currently on the Science Advisory Board of the Animal and Plant Health Agency, UK. She is a RSB Trustee/Council member and represents the RSB on the All-Party Group on STEM at the parliament at Stormont in Northern Ireland. Louise is also a member of the board of the BBSRC and DEFRA funded ‘UK International Coronavirus research and innovation network’.
Session Chairs
Prof. Dr. Silvio Tafuri
Interdisciplinary Department of Medicine, Aldo Moro University of Bari, Bari, Italy
Prof. Dr. Martin J. D'Souza
Department of Pharmaceutical Sciences, Mercer University, Macon, USA
Prof. Dr. Mona O. Mohsen
Department of Biomedical Research, University of Bern, Bern, Switzerland
Dr. Jorge H. Leitão
Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
Dr. Tan Yee Joo
Infectious Diseases Translational Research Programme and Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
Dr. Hatem A. Elshabrawy
Department of Molecular and Cellular Biology, College of Osteopathic Medicine, Sam Houston State University, Huntsville, USA
Assoc. Prof. Srinivasa Reddy Bonam
1. Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, USA; 2. Bapatla College of Pharmacy, Bapatla, India
Prof. Dr. Seth Pincus
Department of Chemistry and Biochemistry, Montana State University, Bozeman, USA
Dr. Henry Nelson Puerta-Guardo
Virology Lab, CIR-Biomedicas, and Campus of Biological and Agricultural Sciences, Autonomous University of Yucatan, Mérida, Mexico
Dr. Bapi Pahar
National Institute of Allergy and Infectious Diseases (NIH/NIAID) Division of Clinical Research (DCR), Integrated Research Facility at Fort Detrick (IRF-Frederick), Frederick, USA
Event Committee
Department of Public Health Policy, School of Public Health, University of West Attica, Greece
Dimitris Zavras is Associate Professor of Health Services Research and Health Economics at the Department of Public Health Policy at the University of West Attica. He is also Faculty Member of the Hellenic Open University. Dimitris was born in Athens in 1968 and studied Physics at the National & Kapodistrian University of Athens. His postgraduate studies include an M.Sc. in Applied Physics from the University of Massachusetts; M.Sc. in Statistics from Athens University of Economics and Business; M.Sc. in Healthcare Management from the National School of Public Health; and a Doctorate (Ph.D.) in Health Services Research and Health Economics from the University of Thessaly (Department of Economics). Dimitris has taught in postgraduate programs of the University of West Attica, the University of Peloponnese, the Neapolis University Pafos (Cyprus), and the National School of Public Health and in undergraduate programs of the University of West Attica, the University of Peloponnese and the Athens University of Applied Sciences. Dimitris Zavras’ research interests focus on healthcare access, utilization of healthcare services, healthcare provider choice, and unmet healthcare needs. His most recent research work and published articles deal with economic issues surrounding the COVID-19 pandemic. He is a member of the International Health Economics Association and the Hellenic Scientific Society of Health Economics and Health Policy. He is also a member of the Hellenic Society for Healthcare Services Management.
Department of Biomedicine and Prevention, University of Rome, Rome, Italy
Department of Statistics and Quantitative Methods, University of Milano-Bicocca, Milano, Italy
Department of Medical Sciences, University of Ferrara, Ferrara, Italy
1. School of Human Sciences, London Metropolitan University, London, UK;,
2. National Heart and Lung Institute, Imperial College London, London, UK
Physician-Scientist, New York, USA
Department of Veterinary Microbiology, Western College of Veterinary Medicine, Saskatoon, Canada
Department of Dermatology, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
College of Pharmacy, University of Illinois, Chicago, USA
Department of Morphology, Experimental Medicine and Surgery, University of Ferrara, Ferrara, Italy
Department of Animal Health, University of Córdoba, Cordoba, Spain
Department of Pharmacology, University of Minnesota, Minnesota, USA
Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, USA
IrsiCaixa AIDS Research Institute, Badalona, Spain
EA4340-BCOH: Biomarker in Cancerology and Onco-Haematology, Université de Versailles Saint- Quentin-En-Yvelines, Boulogne-Billancourt, France
Department of Veterinary Biosciences, The Ohio State University, Columbus, USA
Department of Pharmacology, University of Minnesota, Minnesota, USA
Molecular Pharmacology Program, Laboratory of Signal Transduction, Mortimer B. Zuckerman Research Center, Memorial Sloan Kettering Cancer Center New York, USA
Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, Kingston, USA
Department of Electrical and Computer Engineering, Iowa State University, Iowa, USA
Division of Biomedical and Life Sciences, Furness College, Lancaster University, Lancaster, UK
Department of Radiology, Michigan State University, East Lansing, USA
Protheragen Inc., Holbrook, New York, USA
Laboratory of Microbiology, Democritus University of Thrace, Komotini, Greece
School of Humanities and Social Sciences, Waseda University, Tokyo, Japan
School of Medical and Life Sciences, Sunway University, Selangor, Malaysia
1. Department of Public Health, School of Health Sciences, Ashkelon Academic College, Ashkelon, Israel;,
2. School of Public Health, Faculty of Health Sciences, Ben Gurion University of the Negev, Beersheba, Israel
Department of Women's and Children's Health, K6 Karolinska Institute, Stockholm, Sweden
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, USA
Department of Medicine, Amedeo Avogadro University of Eastern Piedmont, Piedmont, Italy
Vector Biology Section, Laboratory of Malaria and Vector Research, NIAID, NIH, Rockville, Maryland, USA
Division of Infectious Disease and International Medicine, Department of Internal Medicine, University of South Florida, Tampa, USA
Department of Biomedical Sciences, University of Sassari, Sassari, Italy
Keynote Speakers
University of Texas Health Science Center’s Institute of Molecular Medicine (IMM) , USA
Prof. Eva M. Sevick, Ph.D. is At the IMM she leads the National Cancer Institute Center for Translational Research which focuses upon the development and validation of new imaging instrumentation, algorithms, and imaging agents and their clinical translation. She has pioneered the development of near-infrared fluorescence optical imaging and tomography for molecular imaging and currently has two clinical trials underway at the University of Texas Health Science Center and Memorial Hermann Hospital that employ the technology for novel diagnostic imaging of lymphatic function. Her team is active in preclinical, small animal imaging with nuclear and optical techniques and is pioneering diagnostic imaging for nodal staging in cancer. Dr. Sevick received her Ph.D. in Chemical Engineering at Carnegie Mellon University with Rakesh Jain, her post-doctoral training in Biochemistry and Biophysics at the University of Pennsylvania with Britton Chance, and has served on the faculties at Vanderbilt, Purdue, Texas A&M as well as Baylor College of Medicine. She is past recipient of the National Science Foundation Young Investigator Award, the National Institutes of Health Research Career Award, and the American Cancer Society Research Scholar Award and has served as an appointed member of the Biomedical Imaging Study section, associate editor of the IEEE Transactions of Medical Imaging, and officer of the Society of Molecular Imaging.
1. Department of Immunology, University of Bern, Bern, Switzerland,
2. Nuffield Department of Medicine, Jenner Institute, University of Oxford, Oxford, UK
Martin Bachmann studied Cell Biology at the ETH Zürich. In 1995, he earned his PhD Immunology from the ETH Zürich in Switzerland under the supervision of Prof. Zinkernagel in Zürich followed by a Post-Doc at the laboratory of Prof. Ohashi in Canada. After working as a member at the Basel Institute for Immunology and running research at a Biotech company for 10 years, Martin Bachmann became a faculty member and full professor at the University of Bern. Martin is currently professor at the University of Bern and University of Oxford.
Erasmus MC, Rotterdam, Netherlands
Interdisciplinary Department of Medicine, University of Study of Bari, General Hospital, Piazza Giulio Cesare 11, 70124 Bari, Italy
Invited Speakers
Institute of Research in Biomedicine, Universita della Svizzera italiana, Switzerland
Roger Geiger obtained his Master’s and PhD degrees from ETH Zürich. During his PhD studies with Ari Helenius, he investigated how non-enveloped viruses penetrate host cell membranes. He then joined Antonio Lanzavecchia’s laboratory at the Institute for Research in Biomedicine (IRB) as a SystemsX postdoctoral fellow, focusing on the metabolic regulation of T cell responses. In 2016, Roger joined Matthias Mann’s research group at the Max Planck Institute of Biochemistry in Munich, where he received training in mass spectrometry-based proteomics. In 2017, he established his research group at the IRB, aiming to study immune responses to tumors using systems biology approaches. He is Associate Professor at USI, EMBO Young Investigator, and has been awarded an ERC Starting Grant and a Consolidator Grant.
Department of Immunology, University of Bern, Bern, Switzerland
School of Veterinary Medicine, University College Dublin, Dublin, Ireland
Registration
The registration for IECV 2024 will be free of charge! The registration includes attendance to all conference sessions.
If you are registering several people under the same registration, please do not use the same email address for each person, but their individual university email addresses. Thank you for your understanding.
Please note that the submission and registration are two separate parts. Only scholars who registered can receive a link to access the conference live streaming. The deadline for registration is 24th November 2024.
Instructions for Authors
IECV 2024 will accept abstracts only. The accepted abstracts will be available online on Sciforum.net during and after the conference.
Important Deadlines
- Deadline for abstract submission: 16 August 2024 16 September 2024
- Announcement of oral and poster abstract results:10 September 2024 30 September 2024. You will be notified of the acceptance of an oral/poster presentation in a separate email.
Certificates of Participation are available in your logged-in area of Sciforum.net, under “My Certificates” after the conference.
1. The abstract structure should include the introduction, methods, results, and conclusions sections of about 200–300 words in length.
2. All abstracts should be submitted and presented in clear, publication-ready English with accurate grammar and spelling.
3. You may submit multiple abstracts. However, only one abstract will be selected for oral presentation.
Detailed Requirements:
1. The submitting author must ensure that all co-authors are aware of the contents of the abstract.
2. Please select only one presenter for each submission. If you would like to change the presenter after submission, please email us accordingly.
Note: We only accept live presentations.
- Poster should include the title, authors, contact details and main research findings, as well as tables, figures and graphs where necessary.
- File format: PDF (.pdf).
- Size in pixel: 1080 width x 1536 height–portrait orientation.
- Size in cm: 38,1 width x 54,2 height–portrait orientation.
- Font size: ≥16.Examples of successful submissions can be viewed here at the following links: (1), (2), (3).
You can use our free template to create your poster. The poster template can be downloaded HERE.
Authors who wish to present a poster are invited to send it to the conference email at iecv2024@mdpi.com. All posters will be permanently exhibited online in the Poster Gallery.
It is the author's responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there is no conflict, please state "The authors declare no conflicts of interest." This should be conveyed in a separate "Conflict of Interest" statement preceding the "Acknowledgments" and "References" sections at the end of the manuscript. Any financial support for the study must be fully disclosed in the "Acknowledgments" section.
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe authors should retain the copyright to their scholarly works. Hence, by submitting an abstract to this conference, you retain the copyright to the work, but you grant MDPI the non-exclusive right to publish this abstract online on the Sciforum.net platform. This means you can easily submit your full paper (with the abstract) to any scientific journal at a later stage and transfer the copyright to its publisher if required.
Publication Opportunities
Participants in this conference are cordially invited to contribute a full manuscript to the conference's Special Issue, published in Vaccines (ISSN 2076-393X, Impact Factor 5.2), with a 10% discount on the publication fee. Please note that no other discounts are applicable. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper.
All accepted abstracts will be published in the conference report of The 2nd International Electronic Conference on Vaccines in Medical Sciences Forum (ISSN: 2673-9992); if you wish to publish an extended proceeding paper (4-8 pages), please submit it to the same journal after the conference. There will be no additional fees.
Proceedings submission deadline: 15 January 2025.
Manuscripts for the proceedings issue must be formatted as follows:
Title.
Full author names.
Affiliations (including full postal address) and authors' e-mail addresses.
Abstract.
Keywords.
Introduction.
Methods.
Results and Discussion.
Conclusions.
Acknowledgements.
References.
IECV 2024 Proceeding Paper Template
Event Awards
To acknowledge the support of the conference's esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to announce that the conference will provide 6 awards including Best Oral Presentation Awards and Best Poster Awards.
The Awards
Number of Awards Available: 6
The Best Poster Awards are given to the submission judged to make the most significant and interesting poster for the conference.
Sponsors and Partners
For information regarding sponsorship and exhibition opportunities, please click here.
Organizers
Media Partners
Conference Secretariat
Ms. Amy Chen
Ms. Cynthia Wang
Ms. Theodora Felegean
Email: iecv2024@mdpi.com
For inquiries regarding submissions and sponsorship opportunities, please feel free to contact us.
